Selected research
Market Structure
Global Opioids Agonist Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Opioids Agonist Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Opioids Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Opioids Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Opioids Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Opioids Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Opioids Agonist Drugs include Janssen Pharmaceuticals, Inc, Sun Pharmaceuticals, Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc, AbbVie Inc., Titan pharmaceuticals, Purdue Pharma and Mallinckrodt Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Opioids Agonist Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Opioids Agonist Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Opioids Agonist Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Opioids Agonist Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Opioids Agonist Drugs Segment by Company
Janssen Pharmaceuticals, Inc
Sun Pharmaceuticals
Sanofi
Johnson & Johnson Services, Inc.
Pfizer Inc
AbbVie Inc.
Titan pharmaceuticals
Purdue Pharma
Mallinckrodt Pharmaceuticals
Hikma Pharmaceuticals PLC
Grünenthal
Endo Pharmaceuticals Inc.
Egalet Corporation
Boehringer Ingelheim
Allergan, Plc
Opioids Agonist Drugs Segment by Type
Fentanyl
Codeine
Morphine
Methadone
Meperidine
Hydrocodone
Opioids Agonist Drugs Segment by Application
Pain Management
Cough Treatment
Diarrhea Treatment
Opioids Agonist Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioids Agonist Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Opioids Agonist Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioids Agonist Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Opioids Agonist Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Opioids Agonist Drugs industry.
Chapter 3: Detailed analysis of Opioids Agonist Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Opioids Agonist Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fentanyl
- Codeine
- Morphine
- Methadone
- Meperidine
- Hydrocodone
Applications
- Pain Management
- Cough Treatment
- Diarrhea Treatment
Companies covered
- Janssen Pharmaceuticals, Inc
- Sun Pharmaceuticals
- Sanofi
- Johnson & Johnson Services, Inc.
- Pfizer Inc
- AbbVie Inc.
- Titan pharmaceuticals
- Purdue Pharma
- Mallinckrodt Pharmaceuticals
- Hikma Pharmaceuticals PLC
- Grünenthal
- Endo Pharmaceuticals Inc.
- Egalet Corporation
- Boehringer Ingelheim
- Allergan, Plc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Opioids Agonist Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Fentanyl
- 1.2.3 Codeine
- 1.2.4 Morphine
- 1.2.5 Methadone
- 1.2.6 Meperidine
- 1.2.7 Hydrocodone
- 1.3 Market Analysis by Application
- 1.3.1 Global Opioids Agonist Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Pain Management
- 1.3.3 Cough Treatment
- 1.3.4 Diarrhea Treatment
- 1.4 Global Market Growth Prospects
- 1.5 Global Opioids Agonist Drugs Growth Trends by Region
- 1.5.1 Global Opioids Agonist Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Opioids Agonist Drugs Market Size by Region (2021-2026)
- 1.5.3 Opioids Agonist Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Opioids Agonist Drugs Market Dynamics
- 2.1 Opioids Agonist Drugs Industry Trends
- 2.2 Opioids Agonist Drugs Industry Drivers
- 2.3 Opioids Agonist Drugs Industry Opportunities and Challenges
- 2.4 Opioids Agonist Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Opioids Agonist Drugs Revenue by Company (2021-2026)
- 3.2 Global Opioids Agonist Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Opioids Agonist Drugs Key Company Head office and Area Served
- 3.4 Global Opioids Agonist Drugs Company, Product Type & Application
- 3.5 Global Opioids Agonist Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Opioids Agonist Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Opioids Agonist Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Opioids Agonist Drugs Tier 1, Tier 2, and Tier 3
4 Opioids Agonist Drugs Market by Type
- 4.1 Global Opioids Agonist Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Opioids Agonist Drugs Market Size by Type (2021-2032)
- 4.3 Global Opioids Agonist Drugs Market Size Share by Type (2021-2032)
5 Opioids Agonist Drugs Market by Application
- 5.1 Global Opioids Agonist Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Opioids Agonist Drugs Market Size by Application (2021-2032)
- 5.3 Global Opioids Agonist Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Janssen Pharmaceuticals, Inc
- 6.1.1 Janssen Pharmaceuticals, Inc Company Information
- 6.1.2 Janssen Pharmaceuticals, Inc Business Overview
- 6.1.3 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Janssen Pharmaceuticals, Inc Opioids Agonist Drugs Product Portfolio
- 6.1.5 Janssen Pharmaceuticals, Inc Recent Developments
- 6.2 Sun Pharmaceuticals
- 6.2.1 Sun Pharmaceuticals Company Information
- 6.2.2 Sun Pharmaceuticals Business Overview
- 6.2.3 Sun Pharmaceuticals Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Sun Pharmaceuticals Opioids Agonist Drugs Product Portfolio
- 6.2.5 Sun Pharmaceuticals Recent Developments
- 6.3 Sanofi
- 6.3.1 Sanofi Company Information
- 6.3.2 Sanofi Business Overview
- 6.3.3 Sanofi Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Sanofi Opioids Agonist Drugs Product Portfolio
- 6.3.5 Sanofi Recent Developments
- 6.4 Johnson & Johnson Services, Inc.
- 6.4.1 Johnson & Johnson Services, Inc. Company Information
- 6.4.2 Johnson & Johnson Services, Inc. Business Overview
- 6.4.3 Johnson & Johnson Services, Inc. Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Johnson & Johnson Services, Inc. Opioids Agonist Drugs Product Portfolio
- 6.4.5 Johnson & Johnson Services, Inc. Recent Developments
- 6.5 Pfizer Inc
- 6.5.1 Pfizer Inc Company Information
- 6.5.2 Pfizer Inc Business Overview
- 6.5.3 Pfizer Inc Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Pfizer Inc Opioids Agonist Drugs Product Portfolio
- 6.5.5 Pfizer Inc Recent Developments
- 6.6 AbbVie Inc.
- 6.6.1 AbbVie Inc. Company Information
- 6.6.2 AbbVie Inc. Business Overview
- 6.6.3 AbbVie Inc. Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 AbbVie Inc. Opioids Agonist Drugs Product Portfolio
- 6.6.5 AbbVie Inc. Recent Developments
- 6.7 Titan pharmaceuticals
- 6.7.1 Titan pharmaceuticals Company Information
- 6.7.2 Titan pharmaceuticals Business Overview
- 6.7.3 Titan pharmaceuticals Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Titan pharmaceuticals Opioids Agonist Drugs Product Portfolio
- 6.7.5 Titan pharmaceuticals Recent Developments
- 6.8 Purdue Pharma
- 6.8.1 Purdue Pharma Company Information
- 6.8.2 Purdue Pharma Business Overview
- 6.8.3 Purdue Pharma Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Purdue Pharma Opioids Agonist Drugs Product Portfolio
- 6.8.5 Purdue Pharma Recent Developments
- 6.9 Mallinckrodt Pharmaceuticals
- 6.9.1 Mallinckrodt Pharmaceuticals Company Information
- 6.9.2 Mallinckrodt Pharmaceuticals Business Overview
- 6.9.3 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Mallinckrodt Pharmaceuticals Opioids Agonist Drugs Product Portfolio
- 6.9.5 Mallinckrodt Pharmaceuticals Recent Developments
- 6.10 Hikma Pharmaceuticals PLC
- 6.10.1 Hikma Pharmaceuticals PLC Company Information
- 6.10.2 Hikma Pharmaceuticals PLC Business Overview
- 6.10.3 Hikma Pharmaceuticals PLC Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Hikma Pharmaceuticals PLC Opioids Agonist Drugs Product Portfolio
- 6.10.5 Hikma Pharmaceuticals PLC Recent Developments
- 6.11 Grünenthal
- 6.11.1 Grünenthal Company Information
- 6.11.2 Grünenthal Business Overview
- 6.11.3 Grünenthal Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Grünenthal Opioids Agonist Drugs Product Portfolio
- 6.11.5 Grünenthal Recent Developments
- 6.12 Endo Pharmaceuticals Inc.
- 6.12.1 Endo Pharmaceuticals Inc. Company Information
- 6.12.2 Endo Pharmaceuticals Inc. Business Overview
- 6.12.3 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Endo Pharmaceuticals Inc. Opioids Agonist Drugs Product Portfolio
- 6.12.5 Endo Pharmaceuticals Inc. Recent Developments
- 6.13 Egalet Corporation
- 6.13.1 Egalet Corporation Company Information
- 6.13.2 Egalet Corporation Business Overview
- 6.13.3 Egalet Corporation Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Egalet Corporation Opioids Agonist Drugs Product Portfolio
- 6.13.5 Egalet Corporation Recent Developments
- 6.14 Boehringer Ingelheim
- 6.14.1 Boehringer Ingelheim Company Information
- 6.14.2 Boehringer Ingelheim Business Overview
- 6.14.3 Boehringer Ingelheim Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Boehringer Ingelheim Opioids Agonist Drugs Product Portfolio
- 6.14.5 Boehringer Ingelheim Recent Developments
- 6.15 Allergan, Plc
- 6.15.1 Allergan, Plc Company Information
- 6.15.2 Allergan, Plc Business Overview
- 6.15.3 Allergan, Plc Opioids Agonist Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Allergan, Plc Opioids Agonist Drugs Product Portfolio
- 6.15.5 Allergan, Plc Recent Developments
7 North America
- 7.1 North America Opioids Agonist Drugs Market Size (2021-2032)
- 7.2 North America Opioids Agonist Drugs Market Size by Type
- 7.2.1 North America Opioids Agonist Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Opioids Agonist Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Opioids Agonist Drugs Market Share by Type (2021-2032)
- 7.3 North America Opioids Agonist Drugs Market Size by Application
- 7.3.1 North America Opioids Agonist Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Opioids Agonist Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Opioids Agonist Drugs Market Share by Application (2021-2032)
- 7.4 North America Opioids Agonist Drugs Market Size by Country
- 7.4.1 North America Opioids Agonist Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Opioids Agonist Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Opioids Agonist Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Opioids Agonist Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Opioids Agonist Drugs Market Size (2021-2032)
- 8.2 Europe Opioids Agonist Drugs Market Size by Type
- 8.2.1 Europe Opioids Agonist Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Opioids Agonist Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Opioids Agonist Drugs Market Share by Type (2021-2032)
- 8.3 Europe Opioids Agonist Drugs Market Size by Application
- 8.3.1 Europe Opioids Agonist Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Opioids Agonist Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Opioids Agonist Drugs Market Share by Application (2021-2032)
- 8.4 Europe Opioids Agonist Drugs Market Size by Country
- 8.4.1 Europe Opioids Agonist Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Opioids Agonist Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Opioids Agonist Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Opioids Agonist Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Opioids Agonist Drugs Market Size (2021-2032)
- 9.2 China Opioids Agonist Drugs Market Size by Type
- 9.2.1 China Opioids Agonist Drugs Market Size by Type (2021-2026)
- 9.2.2 China Opioids Agonist Drugs Market Size by Type (2027-2032)
- 9.2.3 China Opioids Agonist Drugs Market Share by Type (2021-2032)
- 9.3 China Opioids Agonist Drugs Market Size by Application
- 9.3.1 China Opioids Agonist Drugs Market Size by Application (2021-2026)
- 9.3.2 China Opioids Agonist Drugs Market Size by Application (2027-2032)
- 9.3.3 China Opioids Agonist Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Opioids Agonist Drugs Market Size (2021-2032)
- 10.2 Asia Opioids Agonist Drugs Market Size by Type
- 10.2.1 Asia Opioids Agonist Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Opioids Agonist Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Opioids Agonist Drugs Market Share by Type (2021-2032)
- 10.3 Asia Opioids Agonist Drugs Market Size by Application
- 10.3.1 Asia Opioids Agonist Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Opioids Agonist Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Opioids Agonist Drugs Market Share by Application (2021-2032)
- 10.4 Asia Opioids Agonist Drugs Market Size by Country
- 10.4.1 Asia Opioids Agonist Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Opioids Agonist Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Opioids Agonist Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Opioids Agonist Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Opioids Agonist Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Opioids Agonist Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Opioids Agonist Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Opioids Agonist Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Opioids Agonist Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Opioids Agonist Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Opioids Agonist Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Opioids Agonist Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Opioids Agonist Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Opioids Agonist Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Opioids Agonist Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Opioids Agonist Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Opioids Agonist Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Opioids Agonist Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst